drug_type
RELEVANT_DRUG
intervention_type
bispecific monoclonal antibody (CD20×CD3 T‑cell engager)
drug_description
A CD20×CD3 bispecific monoclonal antibody T‑cell engager that binds bivalently to CD20 on B cells and monovalently to CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and drive T‑cell–mediated cytotoxicity against CD20+ lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Glofitamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
CD20×CD3 bispecific antibody that binds bivalently to CD20 on B cells and monovalently to CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling and drives T‑cell–mediated cytotoxicity against CD20‑positive lymphoma cells.
drug_name
Glofitamab (Columvi)
nct_id_drug_ref
NCT06552572